Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05620784 · ClinicalTrials.gov registry record · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
A Phase 3 study of BPH and BPH With Urinary Obstruction, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 138
- Enrollment target
- 1
- Study location
NCT05620784: Recruiting Phase 3 study of BPH and BPH With Urinary Obstruction, sponsored by Northwestern University.
NCT05620784 is a Phase 3 study of BPH and BPH With Urinary Obstruction that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 138 participants, above the 43-participant average among 5 other BPH trials with a reported enrollment target (221% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05620784, a Phase 3 study of BPH and BPH With Urinary Obstruction, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 138 participants
- Enrollment target
- 1
- Study location
Study Summary
Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for benign prostatic hypertrophy (BPH) as recommended by the American Urological Association (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the morcellation portion of HoLEP to promote urine production in the post-operative setting and to minimize the impact of fluid absorption during long periods of morcellation. The intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated with the dissemination of HoLEP across North America without evidence to support its routine administration. With increasing surgical efficiency from improvements in laser and morcellator technology, the role of intra-operative furosemide is unknown. This study is designed to assess if there is a significant difference in same day discharge rates after Holmium Laser Enucleation of the Prostate (HoLEP) with and without IV furosemide. .
Primary Outcome
Rate of successful same-day discharge after HoLEP
Conditions Studied
Interventions
- DRUG Furosemide
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2024-08-01 |
| Phase | Phase 3 |
What NCT05620784 shows while recruiting
NCT05620784 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, above the 43-participant average among 5 other BPH trials with a reported enrollment target (221% higher).
The record links to 4 conditions, with BPH appearing as the primary indexed condition, and to 1 intervention - of which Furosemide is the first listed.
NCT05620784 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05620784 about?
NCT05620784 is a clinical study titled "Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP". Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for benign prostatic hypertrophy (BPH) as recommended by the American Urological Association (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the morcellation portion of HoLEP to...
What is the current status of trial NCT05620784?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 138 participants. The study started on 2023-03-01. Estimated completion is 2024-08-01.
What conditions does trial NCT05620784 study?
This clinical trial studies the following conditions: BPH, BPH With Urinary Obstruction, Hematuria, Same Day Discharge.
What interventions are being tested in trial NCT05620784?
The interventions under investigation include: Furosemide (DRUG).
Who is sponsoring clinical trial NCT05620784?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05620784 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for BPH
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
US Imaging for the Assessment of LUTS
RECRUITING
-
Effect of Group Preoperative Pelvic Floor Training for HoLEP
RECRUITING
-
Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)
COMPLETED · NA
-
MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH)
COMPLETED · NA
-
LC Bead LUMI for Prostatic Artery Embolization
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
- NCT05834491 · 138 participants · Phase 2
A Novel Approach to Plantar Fasciitis in the Aging Population
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI